Phase 2 study of VB-111, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent...

Date 27 September 2015
Event European Cancer Congress 2015
Session Central Nervous System
Topics Central Nervous System Malignancies
Presenter Brenner, A.